Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Whitmore
S Elizabeth
SE
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077610:Bexarotene; D004347:Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D007371:Interferon-gamma / Q000037:antagonists & inhibitors; D008213:Lymphocyte Activation / Q000187:drug effects; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000187:drug effects; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013764:Tetrahydronaphthalenes; D007371:Interferon-gamma; D000077610:Bexarotene